Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.

ABSTRACT:

Background

This study aimed to evaluate safety and efficacy of programmed death-1 (PD-1) inhibitor sintilimab plus tyrosine kinase inhibitors (TKI) in a real-word cohort of patients with unresectable hepatocellular carcinoma (uHCC).

Methods

A total of 60 patients treated with sintilimab plus TKI between February 2019 and December 2019 were enrolled. Radiological response was recorded by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline and every 6-12 weeks after treatment initiation. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and HCC-specific modified RECIST (mRECIST).

Results

As of the data cutoff on September 30st, 2020, the median duration of follow-up was 10.4 (4.3-23.9) months. The

SUBMITTER: Xie D 

PROVIDER: S-EPMC8106062 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature